As of 2026-07-19, the Relative Valuation of Intellia Therapeutics Inc (NTLA) is (61.21) USD. This relative valuation is based on P/E multiples. With the latest stock price at 11.38 USD, the upside of Intellia Therapeutics Inc based on Relative Valuation is -638.1%.
The range of the Relative Valuation is (56.37) - (68.74) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.2x - 25.5x | 21.8x |
| Forward P/E multiples | 20.0x - 24.3x | 21.6x |
| Fair Price | (56.37) - (68.74) | (61.21) |
| Upside | -595.6% - -704.3% | -638.1% |
| Date | P/E |
| 2026-07-16 | -4.18 |
| 2026-07-15 | -4.62 |
| 2026-07-14 | -4.71 |
| 2026-07-13 | -4.61 |
| 2026-07-10 | -5.03 |
| 2026-07-09 | -5.47 |
| 2026-07-08 | -5.96 |
| 2026-07-07 | -6.17 |
| 2026-07-06 | -6.32 |
| 2026-07-02 | -6.22 |
| 2026-07-01 | -6.10 |
| 2026-06-30 | -5.99 |
| 2026-06-29 | -5.88 |
| 2026-06-26 | -5.91 |
| 2026-06-25 | -5.68 |
| 2026-06-24 | -5.49 |
| 2026-06-23 | -5.40 |
| 2026-06-22 | -5.58 |
| 2026-06-18 | -5.55 |
| 2026-06-17 | -5.38 |
| 2026-06-16 | -5.15 |
| 2026-06-15 | -5.28 |
| 2026-06-12 | -4.29 |
| 2026-06-11 | -4.37 |
| 2026-06-10 | -4.32 |
| 2026-06-09 | -4.56 |
| 2026-06-08 | -4.78 |
| 2026-06-05 | -4.79 |
| 2026-06-04 | -5.22 |
| 2026-06-03 | -4.61 |
| 2026-06-02 | -4.65 |
| 2026-06-01 | -4.86 |
| 2026-05-29 | -4.98 |
| 2026-05-28 | -4.84 |
| 2026-05-27 | -4.76 |
| 2026-05-26 | -4.46 |
| 2026-05-22 | -4.46 |
| 2026-05-21 | -4.38 |
| 2026-05-20 | -4.34 |
| 2026-05-19 | -4.23 |
| 2026-05-18 | -4.49 |
| 2026-05-15 | -4.84 |
| 2026-05-14 | -4.63 |
| 2026-05-13 | -5.06 |
| 2026-05-12 | -4.95 |
| 2026-05-11 | -5.11 |
| 2026-05-08 | -4.99 |
| 2026-05-07 | -4.85 |
| 2026-05-06 | -4.90 |
| 2026-05-05 | -4.71 |